Insider Ledger
CAMP insider buying and SEC filings, explained
Camp4 Therapeutics Corp · CIK 1736730
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$40K
Insiders who bought
1
Sold (not marked 10b5-1)
$2.5M
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 31, 2026 | Open-market purchase | Kelly Gold (CFO) bought 10,000 shares indirectly (by spouse) at about $3.96 ($40K) in an open-market purchase. New position of 10,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
| Aug 27, 2026 | Sale | Andrew J. Schwab (Director) sold 400,000 shares indirectly (by entity) at $4.04 ($1.6M). Holdings by entity down 16% to 2,033,270 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 31, 2026 |
| Aug 24, 2026 | Sale | Andrew J. Schwab (Director) sold 10 shares indirectly (by entity) at $4.50 ($45). Holdings by entity down <1% to 2,433,270 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 26, 2026 |
| Aug 19–21, 2026 | Sale | Andrew J. Schwab (Director) sold 191,865 shares indirectly (by entity) between Aug 19 and Aug 21 at about $4.59 ($880K). Holdings by entity down 7% to 2,433,280 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 21, 2026 |
| Aug 19, 2026 | Sale | Daniel Tardiff (Chief Scientific Officer) sold 1,738 shares at $4.76 ($8K). Holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 19, 2026 |
| Aug 3, 2026 | Other purchase | Richard A Young (Director) bought 16,378 Common Stock at $1.65 ($27K) in a private placement. Holdings up 10% to 186,388 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Other purchase | Yuri Maricich (Chief Medical Officer) bought 6,551 Common Stock at $1.65 ($11K) in a private placement. Holdings up 108% to 12,611 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Other purchase | Kelly Gold (CFO) bought 6,551 Common Stock at $1.65 ($11K) in a private placement. Holdings up 10% to 74,428 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Other purchase | Josh Mandel-Brehm (CEO and Director) bought 6,551 Common Stock at $1.65 ($11K) in a private placement. Holdings up 2% to 284,968 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
| Aug 3, 2026 | Other purchase | Kush Parmar (10% owner) bought 3,179,558 Pre-Funded Warrant (Right to Buy) indirectly (by entity) at $1.53 ($4.9M), reported as a purchase (code P). New position of 3,179,558 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 6 other reporting owners. | SEC filing Filed Aug 5, 2026 |
16 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CAMP in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.